<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02679144</url>
  </required_header>
  <id_info>
    <org_study_id>NMTRC014</org_study_id>
    <nct_id>NCT02679144</nct_id>
  </id_info>
  <brief_title>Neuroblastoma Maintenance Therapy Trial</brief_title>
  <acronym>NMTT</acronym>
  <official_title>NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Giselle Sholler</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KC Pharma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beat NB Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Because of Ezra</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Spectrum Health Hospitals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter,
      study for patients with neuroblastoma in remission. In this study subjects will receive 730
      Days of oral difluoromethylornithine (DFMO) at a dose of 500 to 1000 mg/m2 BID on each day of
      study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are
      in remission as a strategy to prevent recurrence.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with event free survival (EFS) during study.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of time that participants experience Overall Survival (OS)</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>1 year</time_frame>
    <description>Pharmacokinetic assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>1 year</time_frame>
    <description>Pharmacokinetic assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Peak Plasma Concentration (Tmax)</measure>
    <time_frame>1 year</time_frame>
    <description>Pharmacokinetic assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with ODC (Ornithine decarboxylase) single nucleotide polymorphisms.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">258</enrollment>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Difluoromethylornithine (DFMO)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 500 to 1000 mg/m2 twice daily on each day of study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Difluoromethylornithine (DFMO)</intervention_name>
    <description>Subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 500 to 1000 mg/m2 BID on each day of study.</description>
    <arm_group_label>Difluoromethylornithine (DFMO)</arm_group_label>
    <other_name>eflornithine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients must have a pathologically confirmed diagnosis of neuroblastoma, &lt; 30.99
             years of age and classified as high risk at the time of diagnosis. Exception: patients
             who are initially diagnosed as non-high-risk neuroblastoma, but later converted
             (and/or relapsed) to high risk neuroblastoma are also eligible.

          -  All patients must be in complete remission (CR):

               1. No evidence of residual disease on scan

               2. No evidence of disease metastatic to bone marrow.

          -  Specific Criteria by Stratum:

        Stratum 1: All patients must have completed standard upfront therapy that replicates
        treatment which patients who were enrolled on ANBL0032 received, including:

        intensive induction chemotherapy and (if feasible) resection of primary tumor, followed by:
        consolidation with high-dose chemotherapy with stem cell transplant and radiotherapy,
        followed by: immunotherapy with Ch14.18/IL-2/GM-CSF (dinutuximab) and retinoic acid;.

        All subjects on Stratum 1 must have also met the following criteria:

        • A pre-transplant disease status evaluation that met International Neuroblastoma Response
        Criteria (INRC) for CR (complete response), VGPR (very good partial response), or PR
        (partial response) for primary site, soft tissue metastases and bone metastases. Patients
        who meet those criteria must also meet the protocol-specified criteria for bone marrow
        response prior to transplant as outlined below: No more than 10% tumor involvement (based
        on total nucleated cellular content) seen on any specimen from a bilateral bone marrow
        aspirate/biopsy.

        Stratum 2: Neuroblastoma that is in first complete remission following standard upfront
        therapy different from that described for Stratum 1.

        Stratum 3: Neuroblastoma that failed to have a response of at least PR following induction
        chemotherapy and surgical resection of the primary tumor, but that has achieved CR
        following additional therapy.

        Stratum 4: Patients who have achieved a second or subsequent CR following relapse(s).

          -  Pre-enrollment tumor survey: Prior to enrollment on this study, a determination of
             mandatory disease staging must be performed:

               -  Tumor imaging studies including

               -  Bilateral bone marrow aspirates and biopsy

               -  This disease assessment is required for eligibility and preferably should be done
                  within 2 weeks prior to enrollment, but must be done within a maximum of 4 weeks
                  before enrollment.

          -  Timing from prior therapy:

        Stratum 1: Enrollment no later than 60 days after completion of upfront therapy, (last dose
        of cis-retinoic acid) with a maximum of 6 cycles of cis-retinoic acid maintenance therapy.

        Stratum 2, 3 and 4: Enrollment no later than 60 days from last dose of the most recent
        therapy.

          -  Patients must have a Lansky or Karnofsky Performance Scale score of &gt; 50% and patients
             must have a life expectancy of ≥ 2 months.

          -  All clinical and laboratory studies for organ functions to determine eligibility must
             be performed within 7 days prior to enrollment unless otherwise indicated below.

          -  Patients must have adequate organ functions at the time of registration:

               -  Hematological: Total absolute phagocyte count ≥1000/μL

               -  Liver: Subjects must have adequate liver function

               -  Renal: Adequate renal function

          -  Females of childbearing potential must have a negative pregnancy test. Patients of
             childbearing potential must agree to use an effective birth control method. Female
             patients who are lactating must agree to stop breast-feeding.

          -  Written informed consent in accordance with institutional and FDA (food and drug
             administration) guidelines must be obtained from all subjects (or patients' legal
             representative).

        Exclusion Criteria:

          -  BSA (Body Surface Area) of &lt;0.25 m2.

          -  Investigational Drugs: Subjects who are currently receiving another investigational
             drug are excluded from participation.

          -  Anti-cancer Agents: Subjects who are currently receiving other anticancer agents are
             not eligible. Subjects must have fully recovered from hematological and bone marrow
             suppression effects of prior chemotherapy.

          -  Infection: Subjects who have an uncontrolled infection are not eligible until the
             infection is judged to be well controlled in the opinion of the investigator.

          -  Subjects who, in the opinion of the investigator, may not be able to comply with the
             safety monitoring requirements of the study, or in whom compliance is likely to be
             suboptimal, should be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giselle Sholler, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Spectrum Health Hospitals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Genevieve Bergendahl, MSN</last_name>
    <phone>6162670335</phone>
    <email>genevieve.bergendahl@helendevoschildrens.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alyssa VanderWerff, MS</last_name>
    <phone>6162670327</phone>
    <email>alyssa.vanderwerff@helendevoschildrens.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama, Children's of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bridget Tate</last_name>
      <email>btate@peds.uab.edu</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Alva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Samuel Chimienti</last_name>
      <phone>602-546-0211</phone>
      <email>schimienti@phoenixchildrens.com</email>
    </contact>
    <investigator>
      <last_name>Francis Eshun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Hall</last_name>
      <phone>501-364-2760</phone>
      <email>HallSF@archildrens.org</email>
    </contact>
    <investigator>
      <last_name>Kathleen Neville, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital Oakland-</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Snyder</last_name>
      <email>RSnyder@mail.cho.org</email>
    </contact>
    <investigator>
      <last_name>Anurag Agrawal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehrzad Milburn</last_name>
      <phone>858-966-8155</phone>
    </contact>
    <investigator>
      <last_name>William Roberts, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Newton</last_name>
      <phone>860-545-9337</phone>
      <email>ANewton@connecticutchildrens.org</email>
    </contact>
    <investigator>
      <last_name>Michael Isakoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arnold Palmer Hospital for Children</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica El-Shami</last_name>
      <phone>321-841-8588</phone>
      <email>Jessica.El-Shami@orlandohealth.com</email>
    </contact>
    <investigator>
      <last_name>Don Eslin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>All Children's Hospital Johns Hopkins Medicine</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Crimella</last_name>
      <phone>727-767-2428</phone>
      <email>jcrimel1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Gregory Hale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augusta University Health</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Gray</last_name>
      <email>kigray@augusta.edu</email>
    </contact>
    <investigator>
      <last_name>Coleen McDonough, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kapiolani Medical Center for Women and Children</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Siu, MPH</last_name>
      <phone>808-535-7169</phone>
      <email>andrea.siu@kapiolani.org</email>
    </contact>
    <investigator>
      <last_name>Randal Wada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brooke Millward</last_name>
      <email>millwarb@slhs.org</email>
    </contact>
    <investigator>
      <last_name>Eugenia Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advocate Children's Medical Group</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandy Maki</last_name>
      <email>sandy.maki@advocatehealth.com</email>
    </contact>
    <investigator>
      <last_name>Jason Canner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kentucky Children's Hospital</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy Taylor</last_name>
      <email>ttayl2@email.uky.edu</email>
    </contact>
    <investigator>
      <last_name>Lars Wagner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Baker</last_name>
      <phone>617-636-8885</phone>
      <email>kbaker@tuftsmedicalcenter.org</email>
    </contact>
    <investigator>
      <last_name>Michael Kelly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helen DeVos Children's Hospital</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Steinbrecher</last_name>
      <phone>616-267-0334</phone>
      <email>Julie.Steinbrecher@helendevoschildrens.org</email>
    </contact>
    <investigator>
      <last_name>Deanna Mitchell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giselle Sholler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Clinics on Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Haller</last_name>
      <phone>612-813-5913</phone>
      <email>courtney.haller@childrensmn.org</email>
    </contact>
    <investigator>
      <last_name>Jawhar Rawwas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospitals and Clinics</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Dinkins</last_name>
      <phone>816-302-6893</phone>
      <email>MDinkins@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Keith August, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardinal Glennon Children's Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Maxwell, RN</last_name>
      <phone>314-268-4000</phone>
      <email>maxwellk@slu.edu</email>
    </contact>
    <investigator>
      <last_name>William Ferguson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chreyl Falls</last_name>
      <email>Cheryl.Falls@hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>Derek Hanson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Yaffe</last_name>
      <email>Anna.Yaffe@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Sharon Gardner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Levine Children's Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly McKinney</last_name>
      <phone>980-442-2312</phone>
      <email>Kimberly.McKinney@carolinashealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Javier Oesterheld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myeshia Harmon</last_name>
      <phone>614-722-6039</phone>
      <email>Myeshia.Harmon@nationwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Keri Streby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Randall Children's Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron White</last_name>
      <email>AJWHITE@lhs.org</email>
    </contact>
    <investigator>
      <last_name>Jason Glover, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center and Children's Hospital</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Treadway</last_name>
      <email>streadway@hmc.psu.edu</email>
    </contact>
    <investigator>
      <last_name>Valerie Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sydney Bargeloh</last_name>
      <phone>843-792-2957</phone>
      <email>BROWNSY@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Jaqueline Kraveka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monroe Carrell Jr. Children's Hospital at Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nipun Utreja</last_name>
      <phone>615-936-1522</phone>
      <email>nipun.k.utreja@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Devang Pastakia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dell Children's Blood and Cancer Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Letitia Holden, RN</last_name>
      <phone>512-628-1902</phone>
      <email>lholden@sfcaustin.com</email>
    </contact>
    <investigator>
      <last_name>Virginia Harrod, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Rivas</last_name>
      <phone>214-456-0004</phone>
      <email>michelle.rivas@childrens.com</email>
    </contact>
    <investigator>
      <last_name>Ted Laetsch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer and Hematology Centers</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gemma Browne, BS</last_name>
      <email>glbrowne@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>Peter Zage, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Craig</last_name>
      <email>Jennifer.craig@imail.org</email>
    </contact>
    <investigator>
      <last_name>Mark Fluchel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of The King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabrina Wigginton</last_name>
      <email>Sabrina.Wigginton@chkd.org</email>
    </contact>
    <investigator>
      <last_name>Eric Lowe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://beatcc.org</url>
    <description>Beat Childhood Cancer Consortium Website</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2016</study_first_submitted>
  <study_first_submitted_qc>February 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2016</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Spectrum Health Hospitals</investigator_affiliation>
    <investigator_full_name>Giselle Sholler</investigator_full_name>
    <investigator_title>Study Chair</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eflornithine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

